Dapagliflozin 5 mg Oral Tablets: Indications
Dapagliflozin 5 mg is specifically indicated for improving glycemic control in adults and children aged 10 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise. 1
Primary Indication for 5 mg Dose
The 5 mg dose serves as the starting dose for glycemic control in type 2 diabetes. If additional glucose lowering is needed, the dose can be increased to 10 mg once daily 1.
Key Clinical Uses
For Type 2 Diabetes (5 mg dose):
- Initial therapy in treatment-naïve patients with inadequate glycemic control
- Can be used as monotherapy or in combination with other antidiabetic medications (metformin, sulfonylureas, insulin, etc.)
- Demonstrated HbA1c reductions of 0.68-0.82% in drug-naïve patients 2
- Provides additional benefit of weight reduction (typically 1-3 kg) 2, 3
Important Dosing Distinctions:
The 5 mg dose is NOT used for:
- Heart failure management (requires 10 mg) 4
- Chronic kidney disease protection (requires 10 mg) 1
- Cardiovascular risk reduction in established CV disease (requires 10 mg) 4
Mechanism of Action
Dapagliflozin works by inhibiting SGLT2 transporters in the kidneys, blocking glucose reabsorption and promoting urinary glucose excretion. This mechanism is insulin-independent, making it complementary to other diabetes medications 3, 5.
Renal Considerations for 5 mg Dose
- Safe to use when eGFR ≥45 mL/min/1.73 m² for glycemic control 1
- Not recommended for glycemic control when eGFR <45 mL/min/1.73 m² (likely ineffective due to mechanism of action) 4, 1
- Contraindicated when eGFR <30 mL/min/1.73 m² 4
Common Pitfalls to Avoid
Do not use 5 mg for heart failure or CKD indications - these require the 10 mg dose based on outcomes trial data 4. The cardiovascular and renal benefits were demonstrated specifically with 10 mg daily dosing 4.
Discontinue 3 days before major surgery to prevent postoperative ketoacidosis 4, 1.
Monitor for genital and urinary tract infections, which occur more frequently with dapagliflozin (genital infections 7-14% vs 3% placebo; UTIs 8-14% vs 6% placebo) 6.
Safety Profile
- Low hypoglycemia risk when used alone or with metformin 3, 5
- May cause volume depletion - assess and correct volume status before initiating, especially in elderly patients or those on diuretics 1
- Contraindicated in pregnancy and breastfeeding 4
- Risk of euglycemic diabetic ketoacidosis, particularly in type 1 diabetes (not an approved indication) 1, 7